Legend Biotech launches grant program for myeloma research

Bridgewater, New Jersey - Legend Biotech Corporation, a company listed on NASDAQ under the ticker LEGN, has introduced a new grant program called the Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program. This annual initiative is designed to provide financial support to early-career healthcare professionals who are working on cell therapy strategies aimed at improving multiple myeloma treatment.

The program's application period opens on November 20, 2026, and will offer grants in two distinct categories.

The first category is the Emerging Educator Excellence in CAR-T Award. This award recognizes projects that are making significant strides in advancing clinical practice, research, healthcare delivery, or education within the field of CAR-T cell therapies. The second category is the Emerging Innovator Innovation in CAR-T Award. This award is specifically targeted towards projects that present novel approaches, whether through pilot projects, expansion of existing methods, or truly innovative techniques, with a focus on multiple myeloma.

An independent committee of experts in cellular therapy and hematologic malignancies will be responsible for evaluating grant applications. This committee, which operates separately from Legend Biotech to ensure an unbiased review process, comprises leading figures in the field, including Dr. Melissa Alsina, Dr. Ajai Chari, Dr. Rafael Fonseca, Dr. Sundar Jagannath, Dr. Amrita Krishnan, Dr. Yi Lin, and Dr. Saad Usmani.

The committee's decisions will be made with the utmost impartiality to maintain the integrity of the selection process.

The results of the grant application review process will be communicated to the applicants in December 2026. Successful recipients will then be invited to a special recognition event in 2027, where they will have the opportunity to present their grant proposals and share their work with peers and industry leaders. Legend Biotech, known for its development and marketing of CARVYKTI, a CAR-T cell therapy for relapsed or refractory multiple myeloma in collaboration with Johnson & Johnson, employs over 3,000 individuals and is headquartered in the United States.